Trial Profile
[18F]Fluciclovine Companion Imaging Study to Radium-223 and Radiotherapy in Hormone-Naive Men With Oligometastatic Prostate Cancer to Bone (RROPE) Study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Apr 2022
Price :
$35
*
At a glance
- Drugs Fluciclovine 18F (Primary) ; Radium 223 chloride
- Indications Bone metastases; Carcinoma; Prostate cancer
- Focus Diagnostic use
- Acronyms RROPE
- 19 Apr 2022 Status changed from recruiting to completed.
- 21 Sep 2021 Planned End Date changed from 17 Sep 2023 to 1 Sep 2023.
- 21 Sep 2021 Planned primary completion date changed from 17 Sep 2023 to 1 Sep 2023.